Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Learn about the many novel therapeutics recently approved or under development which target LDL-C and/or triglycerides via different mechanisms than do statins.
A new formulation of angiotensin II has received rapid FDA approval for treatment of distributive shock, which is often refractory to other treatment and has a high mortality rate.
Digitalis has been used for medicinal purposes for hundreds of years--and continues to have value in the cardiovascular armamentarium. Review its history and current clinical role in this paper.
Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study.
Effects of Rosuvastatin and Aspirin on Retinal Vascular Structures in Hypercholesterolemic Patients with Low-to-Moderate Risk of Coronary Artery Disease.
Clinical Outcomes at 2 Years Between Beta-Blockade with ACE Inhibitors or ARBs in Patients with AMI Who Underwent Successful PCI with DES: A Retrospective Analysis of 23,978 Patients in the Korea AMI Registry.
Mission Statement:
The American Journal of Cardiovascular Drugs promotes rational therapy and disease management within the discipline of cardiology by providing a regular program of independent review articles covering all aspects of the management of cardiovascular disorders, particularly the place in therapy of newer and established agents and procedures.
